🚨 Biotech portfolios don’t fail because teams lack talent. They fail because capital is allocated without a disciplined way to compare value across programs.
Most R&D ranking frameworks treat every pipeline asset like it’s competing in the same …

The “Patent Cliff” Isn’t Just a Pharma Problem—It’s a Talent Problem.
Most people talk about the patent cliff as a revenue event: when blockbuster exclusivity ends, margins compress, pipelines get stress-tested, and companies scramble to replace lost…

Stop Overstocking Branded Drugs: Patent Intelligence Is the Wholesaler’s New Risk Control
Branded drug inventory risk is one of those problems that looks manageable—until it isn’t.
A few “late” generic entries. A sudden shift in launch timing. A compet…

Big Pharma has a hiring signal that rarely makes headlines: the patent cliff.
When blockbuster exclusivity ends, the industry doesn’t just feel it in revenue statements—it shows up in headcount, org charts, and the quiet reallocation of talent. The mos…

Biosimilars are no longer a “launch” story—they’re a sourcing strategy story.
If you’re planning a switch from an originator to a biosimilar, the hard part isn’t finding a product. It’s timing, contracting, and risk management across a landscape wher…

Pharma is selling “new” prices for “old” drugs—and the justification is getting more sophisticated.
Here’s the uncomfortable truth behind the headlines: many of the highest-cost therapies on formularies today aren’t truly new. They’re repurposed—someti…

Recruiters don’t just “find” talent in pharma—they triangulate it.
In a field where breakthroughs are incremental, expensive, and fiercely protected, the best scientists rarely announce themselves with a flashy headline. They show up in the record: i…

Pharma has a familiar story for “new” prices: the drug is old, but the value is new.
That’s the pitch behind repurposed medicines—therapies originally approved for one use that later gain new indications, new patient segments, and (often) new price tag…

Pharma has a new playbook—and it’s not always about new science.
In a world where “innovation” is the currency of premium pricing, drugmakers increasingly justify higher costs for repurposed medicines using a familiar narrative: same molecule, new valu…

Russia’s “third wheel” rule is supposed to be a footnote in global pharma—an administrative tweak that doesn’t change the game. But in practice, it’s a signal flare. Patent filings are now acting like an early-warning system for where Russia is headed …